ArticleDigestive diseases and sciences2026
Evaluating the Impact of Visceral Adiposity and Sarcopenia on Outcomes in Hospitalized Patients with Acute Severe Ulcerative Colitis.
Article in Digestive diseases and sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Muscle Matters: Sarcopenia, Visceral Adiposity, and Outcomes of Acute Severe Ulcerative Colitis.Digestive diseases and sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePredicting outcomes in acute severe ulcerative colitis (ASUC) is challenging. Data suggest visceral adiposity may negatively impact ulcerative colitis outcomes. We aimed to evaluate the impact of visceral adiposity and sarcopenia on ASUC outcomes.
methodsPatients hospitalized for ASUC with available abdominopelvic CT imaging within 3 months of admission were retrospectively reviewed. Automated segmentation of subcutaneous adipose tissue (SAT) and visceral adipose tissue(VAT) at the third lumbar vertebrae was performed and reviewed by expert radiologists in Visage AI Accelerator. The primary outcome was colectomy during index hospitalization based on quartiles of VAT and visceral fat index (VFI) (VAT:SAT), sarcopenia, and sarcopenic obesity. Secondary outcomes aimed at assessing response to intravenous corticosteroids (IVCS) and infliximab (IFX). Univariate and multivariate associations with the risk of colectomy at index hospitalization were examined using logistic regression models.
resultsA total of 90 patients (64.4% male, median age 36.5 years) were identified. During the index hospitalization, 32 patients (35.6%) required colectomy. Response to IVCS and IFX was seen in 54.2% (45/86) and 66.7% (18/27) patients, respectively. There were no significant differences in the risk of colectomy, response to IVCS or IFX based on VAT area or VFI. Sarcopenia was associated with a reduced likelihood of IVCS response (HR 0.33; 95% CI 0.11-0.97; p = 0.045). Prior advanced therapy exposure was associated with an increased risk of colectomy (HR 7.95; p < 0.001) and decreased response to IVCS (HR 0.35; p = 0.041) on multivariate analysis and decreased response to IFX on univariate analyses (OR 0.16; p = 0.072).
conclusionIn this cohort, neither visceral adiposity nor sarcopenia significantly impacted the colectomy risk, while sarcopenia was associated with a reduced likelihood of corticosteroid response. Prior advanced therapy exposure negatively impacted all outcomes.
Indexed as
Identifiers
41417292What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.